Message boards index | Help | Search messages | Sign in


+ UKCAB + Public area + News, events, announcments + Pharmaceutical Price Regulation Scheme - Dept. of Health

Pharmaceutical Price Regulation Scheme - Dept. of Health

Print
Pages: 1

kevinkelleher
Guest
Pharmaceutical Price Regulation Scheme - Dept. of Health
Posted on: February 15 2011, 02:40 pm

The National Health Service (NHS) spends about 9 billion a year on branded prescription medicines in the UK. The Pharmaceutical Price Regulation Scheme (PPRS) is the mechanism which the Department of Health (on behalf of the UK health departments) uses to ensure that the NHS has access to good quality branded medicines at reasonable prices. The scheme seeks to achieve a balance between reasonable prices for the NHS and a fair return for the industry to enable it to research, develop and market new and improved medicines.

http://www.dh.gov.uk/en/Healthcare/Medicinespharmacyandindustry/Pharmaceuticalpriceregulationscheme/index.htm
Logged
Mark Platt
Member
Posts: 290
Re: Pharmaceutical Price Regulation Scheme - Dept. of Health
Reply #1 on: February 15 2011, 04:17 pm

Useful though this is, the scheme must be considered in light of the Govts stated intention of moving to a Value Based Pricing scheme for the provision of drugs by the NHS, and on which the DH is currently consulting;
http://www.dh.gov.uk/en/Consultations/Liveconsultations/DH_122760
Since HIV medications have never been subject to NICE consideration, the issue of cost to the NHS has never been a concern for HIV clinicians. However, the introduction of VBP may well mean that new HIV medications do not have as easier entrance into the NHS (or whatever Liberating the NHS leaves or creates), and thus availability to PLWH, unless they can be seen to be delivering against the VBP criterion.
Logged
kevinkelleher
Guest
Use of NICE appraised medicines in the NHS in England - 2009
Reply #2 on: February 16 2011, 09:50 am

Resources

    * Use of NICE appraised medicines in the NHS in England - 2009, Experimental statistics. Bulletin (0.90MB)
    * Data Quality Statement (0.02MB)
    * Feedback form (0.10MB)
    * Have your say - give us your comments on this publication.

Summary

The National Institute for Health and Clinical Excellence (NICE) Technology Appraisal process assesses the clinical and cost effectiveness of new and existing drugs and treatments, and provides guidance on their use by the NHS. As part of the Pharmaceutical Price Regulation Scheme (PPRS) agreement which came into operation on 1st January 2009, the Department of Health (DH) and the Association of the British Pharmaceutical Industry agreed that the DH would review the variation in uptake of selected medicines in the NHS in England.

The NHS Information Centre was asked to produce a bulletin looking at variation in the use of these medicines in relation to the number of eligible patients as estimated by NICE. Data on the number of patients being treated is not available and so predicted use (using the average dose and average length of treatment) was compared with observed use. Data on observed use in 2009 was taken from the primary care prescribing data from NHS Prescribing Services and secondary care data provided by IMSHealth.

In all 47 medicines in 18 groups, relating to 29 technology appraisals, were considered. For 12 groups a comparison could be made (these are presented in Section 1 of the technology section results). For those appraisals where a valid comparison could not be made (these are presented in Section 2 of the technology results), the reasons why the comparison could not be made are presented along with a series of questions inviting the reader to suggest improvements to the method or data.

This is an experimental publication and is the second of a planned annual series. Feedback is requested to help inform how best to estimate uptake to allow meaningful interpretation of any variation across NHS organisations in future. A feedback from is provided.
Key facts

    * Of the 12 groups where a comparison could be made, observed use by the NHS in England was higher than the predicted use for 8 and lower for 3. In the case of drugs used for acute coronary syndrome, the result was lower on one set of assumptions and higher on the alternative.
    * For six groups of drugs no valid comparison could be made for a variety of reasons including a wider range of licensed indicatiosn than NICE had appraised

http://www.ic.nhs.uk/statistics-and-data-collections/primary-care/prescriptions/use-of-nice-appraised-medicines-in-the-nhs-in-england--2009-experimental-statistics
Logged

Print
Pages: 1

+ UKCAB + Public area + News, events, announcments + Pharmaceutical Price Regulation Scheme - Dept. of Health